Omeros (OMER) Projected to Post Earnings on Monday

Omeros (NASDAQ:OMER) is anticipated to release its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect Omeros to post earnings of ($0.55) per share and revenue of $40.1490 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 4:00 PM ET.

Omeros Stock Down 1.1%

Omeros stock opened at $11.00 on Monday. The company has a market capitalization of $779.90 million, a PE ratio of -5.45 and a beta of 2.45. Omeros has a 12-month low of $2.95 and a 12-month high of $17.65. The firm’s fifty day moving average is $11.71 and its 200 day moving average is $9.46.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on OMER. D. Boral Capital reaffirmed a “buy” rating and issued a $36.00 price target on shares of Omeros in a research note on Tuesday, January 27th. HC Wainwright increased their price objective on shares of Omeros from $20.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Omeros in a research report on Thursday, January 22nd. Finally, Wall Street Zen downgraded Omeros from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $40.33.

Insider Buying and Selling

In other Omeros news, CAO David J. Borges sold 30,000 shares of the business’s stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $12.31, for a total transaction of $369,300.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 12.90% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Invesco Ltd. increased its position in shares of Omeros by 26.8% during the fourth quarter. Invesco Ltd. now owns 154,782 shares of the biopharmaceutical company’s stock worth $2,658,000 after acquiring an additional 32,707 shares in the last quarter. Corient Private Wealth LLC lifted its position in Omeros by 12.9% in the 4th quarter. Corient Private Wealth LLC now owns 687,325 shares of the biopharmaceutical company’s stock valued at $11,805,000 after acquiring an additional 78,563 shares in the last quarter. Virtus Investment Advisers LLC bought a new position in Omeros in the 4th quarter valued at about $450,000. Wellington Management Group LLP boosted its stake in Omeros by 4.2% during the 4th quarter. Wellington Management Group LLP now owns 202,617 shares of the biopharmaceutical company’s stock valued at $3,480,000 after purchasing an additional 8,170 shares during the last quarter. Finally, Millennium Management LLC boosted its stake in Omeros by 10.0% during the 4th quarter. Millennium Management LLC now owns 441,811 shares of the biopharmaceutical company’s stock valued at $7,588,000 after purchasing an additional 39,997 shares during the last quarter. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.